Fundz

Who to call at CytoReason, and when

Fundz watches for the moments CytoReason starts buying, and tells you who to reach.

  • An alert the day CytoReason raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CytoReason, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CytoReason. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub

Jul 17, 2024

Contract Type

partnership

Tel AvivBiotechnologyAnalytics

Description

CytoReason secured an aggregated $80 million investment from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale its AI disease models, expand the application of its models into additional indications, grow its proprietary molecular and clinical data, and establish an office in Cambridge, Massachusetts. The company aims to improve the probability of phase 2 success and optimize its R&D portfolio by providing molecular-level insights and AI tools to make data-driven decisions.

Company Information

Company

CytoReason

Location

Tel Aviv, Tel Aviv District, Israel

About

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

Related People

David
Likely contact at this company
••••••••@••••••••

See David's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for CytoReason's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

CytoReason signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.